Cyclopharm Limited (ASX:CYC)

Market Cap	90.60M -46.4%
Revenue (ttm)	32.33M +17.2%
Net Income	-17.22M
EPS	-0.16
Shares Out	120.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,703
Average Volume	253,351
Open	0.8100
Previous Close	0.7900
Day's Range	0.7500 - 0.8100
52-Week Range	0.5600 - 1.5500
Beta	0.80
RSI	40.34
Earnings Date	Feb 24, 2026

About Cyclopharm

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1986
• Employees: 109
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CYC

Financial Performance

In 2025, Cyclopharm's revenue was 32.33 million, an increase of 17.24% compared to the previous year's 27.57 million. Losses were -17.22 million, 30.5% more than in 2024.